Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours

NCT04823897 is registered in ClinicalTrials.gov with PharmaMatrix Holdings Ltd as lead sponsor.

NCT NCT04823897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04823897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours
Lead sponsor
PharmaMatrix Holdings Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
July 26, 2021
Completion date
December 31, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer: recurrent and/or metastatic solid tumours